Skip to main content

Good news: ‘fibrofog’ doesn’t portend Alzheimer’s

By: BRUCE JANCIN,
Family Practice News Digital Network 11/22/13

 SAN DIEGO – ‘Fibrofog’ – the cognitive dysfunction experienced by up to 80% of fibromyalgia patients – is not an early harbinger of Alzheimer’s disease, Dr. Robert S. Katz asserted at the annual meeting of the American College of Rheumatology.

 The problems with memory, concentration, language, and thinking, collectively known as fibrofog, affect fibromyalgia patients in their 20s-50s. The onset is typically more sudden and dramatic than with classic forms of dementia. As fibrofog becomes chronic, many affected fibromyalgia patients – fearing the worst – worry they are on a road to Alzheimer’s disease in middle age.

Not so, according to Dr. Katz, professor of medicine at Rush Medical College, Chicago.

 He presented a cross-sectional study involving two cohorts. One comprised 69 fibromyalgia patients with symptoms of cognitive dysfunction of 12 months duration or less. The other consisted of 39 fibromyalgia patients with fibrofog symptoms of 7-26 years duration. The long-duration group averaged 52.3 years of age, nearly 7 years older than the group with more recent onset of fibrofog. But the two groups were closely similar in terms of educational level, depression scores, and vocabulary scale scores.

 The key study finding: No significant differences existed between the two groups on 13 of the 14 measures of neurocognitive function assessed in the study, including logical memory, paired associate, digit symbol, letter fluency, processing speed, and the Stroop word speed and color speed tests.

 Indeed, the sole metric where the long-duration fibrofog patients fared significantly worse was the Trails A test, a measure of spatial scanning and cognitive sequencing. However, the two groups had closely similar scores on the Trails B.

 Compared with standardized normative means that have been established for each of the 14 neurocognitive tests, the level of cognitive impairment in the fibromyalgia patients was markedly less than that seen in patients with Alzheimer’s disease. More specifically, measures of processing speed and episodic memory, which are significantly diminished in individuals with preclinical Alzheimer’s disease, were within normal range in both study groups. That’s reassuring. So is the fact that the cognitive deficits present in the shorter-duration group weren’t markedly more pronounced in the group troubled by cognitive problems for an additional 6-25 years. Thus, fibrofog does not appear to be a condition characterized by progressive cognitive decline, the rheumatologist observed.

 Dr. Katz reported having no financial conflicts of interest with regard to this study.


 bjancin@frontlinemedcom.com
 Copyright © 2013 International Medical News Group, LLC. All rights reserved. This page was copied from www.familypracticenews.com .

Comments

Popular posts from this blog

Living with Chronic pain hits the big screen!

Been to the movies lately?  Jennifer Aniston is on the big screen in a recent release titled "Cake."
Her character, Claire is a victim of chronic pain...she belongs to a support group, where all of the members are coming to terms with the suicide of one of their members.  Of course, she also takes pain medication and addiction is another of her problems...and of course there's more!

I guess I am writing this post just to bring readers' attention to the fact that Hollywood has become aware of the crisis that is chronic pain.  This movie is a testament to that. People that don't have to live with this kind of pain don't fully understand the whole story.  Maybe this movie will shed some light on the issues.

Here is the official trailer for the movie:


Sources: prweb;NorthJersey.com;YouTube


Herpes As A Helper?

If you've ever had shingles, or known anyone that has experienced it, you probably know that chronic pain can persist following the initial attack (post herpetic neuralgia).  This is because the herpes virus seems to have an affinity for nerve cells.  And while it's not fun to have shingles or post herpetic neuralgia, the herpes virus may be a key in future development of delivery systems for pain management treatments.





Here's the deal--since Herpes simplex has an affinity for nerve cells, researchers are looking a genetically modified, safer version of the virus to deliver genetic material to damaged nerves.  In simple terms, once the genetic material reaches these nerve cells, it will hopefully encode these nerves to ultimately inhibit pain signals.  Animal studies and clinical trials in cancer patients have been encouraging thus far.

This is one of those developments that makes me believe that there is hope for those in chronic pain. Along with so many other exciting d…

The Knee Bone's Connected To The Leg Bone....

Two recent studies have brought a not-so-novel concept into the limelight-the concept being that people who present with knee pain often develop pain in other parts of their bodies.  These studies, known as the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI), were assessed by a Clinical Epidemiology Team as Boston University School of Medicine in an effort to find preventive strategies to combat this trend.




The authors suggest that knee pain may cause individuals to alter their gait in an effort to compensate for their discomfort. In doing so, the alignment of other body joints is altered, and this may be the cause of secondary joint pain, especially hips and ankles. The authors go on to say that the pain in these secondary sites is not necessarily osteoarthritis--perhaps bursitis or some other injury.

Osteoarthritis is a result of wear and tear in the joints.  We may not be able to completely eliminate osteoarthritis from occurring, but some common se…